
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific demonstrates robust financial growth across multiple product lines, highlighted by a remarkable 35% year-over-year increase in Watchman sales and an impressive 63% growth in the electrophysiology sector, reflecting strong market demand and share gains. The company anticipates organic sales growth of 11-13% for the fourth quarter, alongside projected GAAP EPS of $0.48-$0.52, indicating solid overall performance and revenue generation. Additionally, significant growth is expected in innovative areas, such as Nalu's projected sales exceeding $60 million in 2025 and ongoing double-digit increases in various cardiac and diagnostic sectors, affirming a positive trajectory for the firm.
Bears say
The analysis indicates a negative outlook for Boston Scientific due to several factors affecting its revenue growth. The company is expected to face a significant foreign exchange headwind of approximately $0.04 per share for the full year, alongside a slight reduction in future revenue estimates reflecting recent quarterly performance misses. Additionally, pressures within mature market segments, particularly in the cardiac rhythm management and drug-eluting stent portfolios, compounded by challenges in product integration and missed expectations in various segments, further heighten the uncertainty surrounding Boston Scientific's ability to meet internal growth projections.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares